Pierre Blais
Baylor College of Medicine
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Pierre Blais.
The American Journal of Gastroenterology | 2015
Pierre Blais; Nisreen S. Husain; Jennifer R. Kramer; Marc A. Kowalkowski; Hashem B. El-Serag; Fasiha Kanwal
OBJECTIVES:The prevalence and disease burden of nonalcoholic fatty liver disease (NAFLD) are increasing. Nonetheless, little is known about the processes related to identification, diagnosis, and referral of patients with NAFLD in routine clinical care.METHODS:Using automated data, we isolated a random sample of patients in a Veterans Administration facility who had ≥2 alanine transaminase (ALT) values >40 IU/ml >6 months apart in the absence of any positive results for hepatitis C RNA, hepatitis B surface antigen, or screens for excess alcohol use. We conducted a structured medical record review to confirm NAFLD and abstracted data from the primary care providers’ notes for (i) recognition of abnormal ALT levels, (ii) mention of NAFLD as a possible diagnosis, (iii) recommendations for diet or exercise, and (d) referral to a specialist for further NAFLD evaluation. Using a multilevel logistic regression model, we identified patient demographic, clinical, comorbidity, and health-care utilization factors associated with recognition and receipt of early NAFLD care.RESULTS:Of 251 patients identified with NAFLD by our methods, 99 (39.4%) had documentation in medical record notes of abnormal ALT, 54 (21.5%) had NAFLD mentioned as a possible diagnosis, 37 (14.7%) were counseled regarding diet and exercise, and 26 (10.4%) were referred to a specialist. Only the magnitude of ALT elevation (adjusted odds ratio (OR) for ALT >80 IU/ml vs. <80 IU/ml=4.4, 95% confidence interval (CI)=2.65–7.30) and proportion of elevation (adjusted OR for >50% vs. <50% of ALT values >40 IU/ml=1.8, 95% CI=1.03–3.14) were associated with receiving specified NAFLD care. Only 3% of patients at a high risk of fibrosis (NAFLD fibrosis score >0.675) were referred to specialists.CONCLUSIONS:Most patients in care who may have NAFLD are not being recognized and evaluated for this condition. Our data suggest that providers may be using an incorrect heuristic in delivering NAFLD care by concentrating on those with high ALT levels.
Alimentary Pharmacology & Therapeutics | 2014
N. Husain; Pierre Blais; Jennifer R. Kramer; Marc A. Kowalkowski; Paul G. Richardson; Hashem B. El-Serag; Fasiha Kanwal
In practice, nonalcoholic fatty liver disease (NAFLD) is diagnosed based on elevated liver enzymes and confirmatory liver biopsy or abdominal imaging. Neither method is feasible in identifying individuals with NAFLD in a large‐scale healthcare system.
Digestive Diseases and Sciences | 2016
Pierre Blais; Jennifer R. Kramer; Hashem B. El-Serag; Fasiha Kanwal
Gastroenterology | 2015
Pierre Blais; Hashem B. El-Serag; Jennifer R. Kramer; Fasiha Kanwal
Gastroenterology | 2018
Pierre Blais; Alex Huh; Leela Nayak; Jill E. Elwing; Gregory S. Sayuk
Gastroenterology | 2018
Pierre Blais; Michael C. Bennett; C. Prakash Gyawali
Gastroenterology | 2017
Pierre Blais; Christopher T. Sparrow; David S. Raymer; Justin M. Vader; Shane J. LaRue; Chien-Huan Chen
Gastroenterology | 2017
Pierre Blais; Amit Patel; Gregory S. Sayuk; C. Prakash Gyawali
Gastroenterology | 2016
Benjamin Cassell; Saad Alghamdi; Jason Bill; Pierre Blais; Harold J. Boutte; Jeffrey W. Brown; Gregory S. Sayuk; C. Prakash Gyawali
Gastroenterology | 2015
Anam Khan; Aylin Tansel; Donna L. White; Pierre Blais; Jan A. Lindsay; Hashem B. El-Serag; Fasiha Kanwal